

1 **Impact of a multi-disease integrated screening and diagnostic model for COVID-19, TB,**
2 **and HIV in Lesotho**

3
4

5 Bulemba Katende¹, Moniek Bresser^{2,3}, Mashaete Kamele¹, Lebohang Chere⁴, Mosa Tlahali⁵,
6 Rahel Milena Erhardt^{2,3}, Josephine Muhairwe¹, Irene Ayakaka¹, Tracy R Glass^{2,3}, Morten
7 Ruhwald⁶, Bram van Ginneken⁷, Keelin Murphy⁷, Margaretha de Vos⁸, Alain Amstutz⁹,
8 Mathabo Mareka¹⁰, Sekhele Matabo Mooko¹⁰, Niklaus D. Labhardt^{2,3,8}, Klaus Reither^{2,3}, Lucia
9 González Fernández^{2,3,8,11}

10

11 **Authors Affiliation:**

12 ¹ SolidarMed, Partnerships for Health, Maseru, Lesotho

13 ² Swiss Tropical and Public Health Institute, Allschwil, Switzerland

14 ³ University of Basel, Basel, Switzerland

15 ⁴ Butha-Buthe District Health Management Team, Butha-Buthe, Lesotho

16 ⁵ Mokhotlong District Health Management Team, Mokhotlong, Lesotho

17 ⁶ FIND, the global alliance for diagnostics, Geneva, Switzerland

18 ⁷ Diagnostic Image Analysis Group, Radboud UMC, Nijmegen, The Netherlands

19 ⁸ Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel,
20 Basel, Switzerland

21 ⁹ CLEAR Methods Center, Division of Clinical Epidemiology, Department of Clinical Research,
22 University Hospital Basel, University of Basel, Basel, Switzerland

23 ¹⁰ National Reference Laboratory, Ministry of Health of Lesotho, Maseru

24 ¹¹ SolidarMed, Partnerships for Health, Lucerne, Switzerland

25

26 **Correspondence to:**

27 Klaus Reither: klaus.reither@swisstph.ch

28

29 **Keywords:** SARS-CoV-2, COVID-19, HIV, Tuberculosis, integrated TB/COVID-19, sub-
30 Saharan Africa, Lesotho

31

32

33

34

35

36 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 **Abstract 298 words**

38 **Introduction**

39 The surge of the COVID-19 pandemic challenged health services globally, and in Lesotho, the
40 HIV and tuberculosis (TB) services were similarly affected. Integrated, multi-disease
41 diagnostic services were proposed solutions to mitigate these disruptions. We describe and
42 evaluate the effect of an integrated, hospital-based COVID-19, TB and HIV screening and
43 diagnostic model in two rural districts in Lesotho, during the period between December 2020
44 and August 2022.

45 **Methods**

46 Adults and children above 5 years attending two hospitals were screened for COVID-19 and
47 TB symptoms. After a positive screening, participants were offered to enroll in a service model
48 that included clinical evaluation, chest radiography, SARS-CoV-2, Xpert MTB/RIF Ultra and
49 HIV testing. Participants diagnosed with COVID-19, TB, or HIV were contacted after 28 days
50 evaluate their health status, and linkage to HIV or TB services.

51 **Results**

52 Of the 179160 participants screened, 6623(37%) screened positive, and 4371(66%) were
53 enrolled in this service model, yielding a total of 458 diagnoses. One positive rapid antigen
54 test for SARS-CoV-2 was found per 11 participants screened, one Xpert-positive TB case was
55 diagnosed per 85 people screened, and 1 new HIV diagnosis was done per 182 people
56 screened. Of the 321(82.9%) participants contacted after 28 days of diagnosis, 304(94.7%)
57 reported to be healthy. Of the individuals that were newly diagnosed with HIV or TB,
58 18/24(75.0%) and 46/51(90.1%) started treatment. This service showed no difference in the
59 detection of new HIV and TB cases when compared to other hospitals, where no such
60 integrated service model was provided.

61 **Conclusion**

62 This screening and diagnostic model successfully maintained same-day, integrated COVID-
63 19, TB, and HIV testing services through different COVID-19 incidence periods in a resource-
64 limited context. There were positive effects in avoiding diagnostic delays and ensuring linkage
65 to services, however, efficiencies were contingent on the successful adaptation to the
66 changing environment.

67

68 **Introduction**

69 The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the
70 coronavirus disease 2019 (COVID-19) pandemic negatively impacted health services delivery
71 in most countries, even where health systems were thought to be well-established(1–4). At
72 the same time that the pandemic created a significant increase in morbidity and mortality
73 globally, health facilities across the globe shut down or restricted their activity to the provision
74 of essential services. Factors such as infection control risks, lack of health workers or personal
75 protective equipment(5) led to a substantial reduction in access to primary health care
76 worldwide(6). In countries with high TB and HIV prevalence, the COVID-19 pandemic reversed
77 years of progress in the control of these 2 conditions(7,8).

78 Although the African continent reported relatively low COVID-19 cases, compared to other
79 regions in the world, the impact of the pandemic on health service delivery was still very
80 significant. Access to health facility–based services was interrupted as a result of 1) health
81 workers shortages due to illness, self-quarantine, or strikes, 2) health facilities repurposed for
82 COVID-19 treatment, covering minimum services, or closed completely, and 3) clients'
83 reluctance to attend to visits, due to fear of increased risk of COVID-19 exposure, or
84 decreased availability of public transportation(6,9,10). A review by Gizachew A. Tessema *et*
85 *al.* reported substantial reduction in access to essential and general health services across
86 the African continent(11), and in South Africa, a study in the KwaZulu Natal province reported

87 an estimated 47.6% and 46.2% decrease in HIV testing and anti-retroviral therapy initiation
88 respectively(12).

89 Lesotho is a country in the sub-Saharan region with over 2 million population(13). The
90 estimated TB incidence sits at 614%, the HIV prevalence is 20.9%, and there is approximately
91 55% TB/HIV coinfection(14–16). Similar to other settings, the health system and health
92 services in Lesotho were similarly affected by the COVID-19 pandemic(17–21). The first
93 COVID-19 case was reported in May 2020, and up to December 2022, approximately 34,490
94 COVID-19 cases and 706 COVID-19 related deaths have been reported. Although cases have
95 been recorded continuously since May 2020, three significant waves were described, with
96 high incident rates in December 2020, June to September 2021, and December 2021(22). To
97 reinforce the efforts against the spread of SARS-CoV-2, the government of Lesotho set up a
98 public health strategy that regulated social norms to ensure physical distance between people.
99 A COVID-19 Risk Determination and Mitigation Framework was created as a 5-colour scale,
100 regulating daily life activities, depending on the COVID-19 reproductive number (R0)
101 determined regularly. The scale of colors varied from green, blue, purple, yellow, and red.
102 Green color was associated with $R_0 < 1$ and red color was associated with $R_0 > 2.5$. Typically,
103 at each subsequent level, social measures became more stringent, and included mandates,
104 such as staying home, avoiding crowds, or closure of business and borders (23–28).

105 In this context, the project named *Mitigation strategies for communities with COVID-19 in*
106 *Lesotho* -MistraL-(29) was conceived as an initiative to expand COVID-19 diagnosis and
107 integrate TB and HIV testing in the districts of Butha-Buthe and Mokhotlong, situated in the
108 northeast part of the country (figure 1). From December 2020 to August 2022, MistraL
109 reinforced the health system response (table 1), contributing to aspects such as: 1) support to
110 the COVID-19 response coordination at district and national level; 2) addition of resources to
111 improve health facilities infrastructure and provision of medical equipment; 3) integration of
112 COVID-19/TB/HIV testing and linkage model; 4) addition and training of health workers for
113 provision of services; and 5) implementation of research activities, including SARS-CoV-2

114 RTT tests validation in nasopharyngeal and nasal samples, or use and validation a of
115 computer- aided diagnostic software for COVID-19 (CAD4COVID).

116 In recent years, there has been an increasing interest to understand whether and how
117 integrated screening and testing services could provide access to prompt COVID-19 diagnosis
118 and management, while maintaining diagnostic and linkage services for TB and HIV, in an
119 epidemic context(30–32). Nonetheless, to date, there have been few studies demonstrating
120 feasibility or wider impact of such services in sub-Saharan Africa(33–35). The objective of this
121 study is to describe and assess the effect of a pragmatic COVID-19/TB and HIV integrated
122 screening and testing service model for adults and children older than 5 years in two remote
123 referral hospitals in Lesotho.

124

125 **Methods**

126 **Context**

127 We implemented this screening and diagnostic model at the St Charles Missionary Hospital
128 Seboche and the Mokhotlong Government District Hospital, in the districts of Butha-Buthe and
129 Mokhotlong. These districts are characterized by mostly rural settings with an estimated
130 combined population of 250,000 people, who are mainly subsistence farmers, mine workers
131 or construction and domestic laborers who work in neighboring South Africa. Each district has
132 only one single mid-size town: Butha-Buthe with ca. 25,000 inhabitants and Mokhotlong with
133 ca. 10,000 inhabitants. The remaining population lives in villages scattered over a
134 mountainous area of 5,842 km². Health services in these two districts are provided through a
135 network of clinics and hospitals. In Butha-Buthe district health care is available through 10
136 nurse-led rural health centers, 1 missionary hospital, and 1 governmental hospital. In
137 Mokhotlong services are available through 9 nurse-led rural health centers, and 1
138 governmental hospital.

139

140 **Integrated TB/COVID-19 and HIV screening and testing model**

141 A nurse-led, multi-disease, integrated screening and diagnostic model was established, with
142 the aim to provide same-day, one-stop shop diagnosis and clinical evaluation. After the
143 diagnostic procedures were done, the nurses would manage cases themselves, or refer to
144 other hospital staff, according to established clinical algorithms (figure 2). This service was
145 continuously adapted to the needs and diagnostic standards, driven by a fast-changing
146 context.

147 ***Screening, eligibility, and enrolment***

148 Adults and children seeking health services, visitors, and staff attending daily work, were pre-
149 screened by trained TB/COVID-19 lay screeners. Pre-screening took place in specially built
150 structures by the gates of the two hospitals and focused on the investigation of history of close
151 contact with a COVID-19 case or the presence of at least one sign or symptom of TB or
152 COVID-19. The initial evaluation included: fever measured (≥ 38 °C, forehead or reported),
153 cough of any duration, pronounced tiredness, shortness of breath, sore throat, muscle or body
154 pain, diarrhoea, loss of taste/smell, weight loss, night sweat. We defined close contact with a
155 (confirmed or probable) COVID-19 case, as a contact within one meter for more than 15
156 minutes, or direct physical contact with a (probable or confirmed) case, or direct care provided
157 to a patient with (probable or confirmed COVID-19) disease without using proper personal
158 protective equipment. A significant contact of TB was determined using the standard
159 definition(36). We defined positive pre-screening as the presence of at least one sign or
160 symptom, or a history of close contact with a COVID-19 or TB case. People who pre-screened
161 positive and were 5 years or older, were referred to a nurse, who determined eligibility to enroll
162 in this diagnostic model, explained the testing procedures, and obtained informed consent.
163 Once the participant was enrolled, the nurse took medical history focusing on COVID-19, TB,
164 and HIV, measured BMI, body temperature, and performed a clinical examination to assess
165 the severity of respiratory symptoms. We defined mild, moderate and severe clinical
166 presentation as follows: 1) mild disease included the presence of COVID-19 signs and

167 symptoms, without hypoxia or dyspnea; 2) moderate disease included the presence of signs
168 and symptoms of pneumonia (fever, cough, dyspnea, tachypnoea) or an oxygen saturation \leq
169 94%, with no signs of severe pneumonia; and 3) severe disease included the presence of at
170 least one of the following: altered mental status, oxygen saturation $< 94\%$ or signs of central
171 cyanosis, shortness of breath or difficulty breathing, fast breathing (5-9 y ≥ 30 breaths/min;
172 ≥ 10 y ≥ 20 breaths/min; and ≥ 18 y ≥ 22 breaths/min), systolic blood pressure < 100 mmHg in
173 adults and general danger signs in children. For severely ill participants, the nurse referred
174 them to a physician in the hospital immediately after the clinical examination and patients
175 followed the integrated diagnostic procedures only if the physician judged that these would
176 benefit them. Patients with mild or moderate symptoms at presentation remained in the study
177 and were offered all the clinical procedures. Enrolled participants had a digital posterior-
178 anterior chest Xray done and analyzed using artificial intelligence-powered, computer-aided
179 detection software for TB (CAD4TB version 6; Delft Imaging Systems, the Netherlands). Those
180 with a result score of 50 or above followed investigations for TB(37).

181 ***TB, COVID-19, and HIV diagnosis***

182 Diagnosis of SARS-CoV-2 infection was done using RDTs or PCR, in different combinations
183 that varied along the implementation period, adapting to the enrolment of different studies,
184 and the evolving diagnostic recommendations for SARS-CoV-2 in Lesotho. We used the
185 STANDARD Q COVID-19 Antigen test (SD Biosensor, Republic of Korea) with a nasal or a
186 nasopharyngeal swab, and PCR (ABI 7500 Real-Time PCR platform, Applied Biosystem, USA
187 and Xpert Xpress SARS-CoV-2 Cepheid, USA) . All participants included in this study had at
188 least one nasopharyngeal SARS-CoV-2 RDT result. Participants who presented with
189 presumptive TB symptoms or a CAD4TB score > 50 were requested to submit sputum for TB
190 diagnostic testing using the Xpert MTB/RIF Ultra (PCR GeneXpert, Cepheid, Sunnyvale, CA,
191 USA). Participants who were requested to submit sputum watched a video describing how to
192 produce a quality sputum before they attempted to produce the sample. For HIV diagnosis,
193 we followed standard of care in Lesotho, that included a first assessment using an HIV risk

194 screening tool to determine HIV testing eligibility. If participants were found to be high risk
195 using the HIV testing screening tool, they were tested following the Lesotho HIV guidelines
196 that used standard blood based RDTs(38). For the purpose of this study, we defined a COVID-
197 19 case as an individual with a positive result in either RDT (nasopharyngeal or nasal swab)
198 or PCR (nasopharyngeal swab). TB diagnosis was defined as a positive Xpert MTB/RIF Ultra
199 result in sputum, and an HIV diagnosis was defined according to Lesotho standard testing
200 algorithm.

201 ***Follow up after 28 days after testing***

202 To measure the effect of this integrated multi-disease diagnostic service, in terms of linkage
203 to COVID-19 curative services, TB and HIV treatment initiation, all enrolled participants that
204 had at least one TB, COVID-19 (RDT or PCR) or HIV positive result, were followed up in a
205 window of time around 28 days after enrolment. A study nurse attempted to contact each
206 participant or their next in kin, through a phone call. In the case of participants diagnosed with
207 COVID-19, we collected information on whether they were “healthy” (had recovered from
208 symptoms, after the episode), “hospitalized” (still admitted due to the condition) or deceased.
209 For participants that were newly diagnosed with TB or HIV, we asked whether they had started
210 treatment after diagnosis and checked hospital records (TB and HIV registers) at the two
211 hospitals.

212 **Ethical Consideration**

213 All procedures were carried out in line with the ethical standards laid out in the Declaration of
214 Helsinki(39). Participants that enroll in this diagnostic model received information on the
215 clinical procedures in Sesotho and gave written informed consent and those who were illiterate
216 gave consent by thumbprint and a witness signature. Parents or guardians of all participants
217 below 18 years signed an informed consent form, while participants between 7 and 17 years
218 additionally signed an assent form. This project was approved by the Lesotho Ministry of

219 Health Ethics Committee (ID 107-2020) and by the Ethic Committee Switzerland
220 (Ethikkommission Nordwest- und Zentralschweiz (EKNZ) AO_2020-00018).

221

222 **Data collection and analysis**

223 Clinical data was collected by trained nurses using the Open Data Kit (ODK) software(40).
224 Information that could not be obtained on the same day, such as Xpert MTB/RIF Ultra and
225 SARS-CoV-2 PCR results, was uploaded to ODK as soon as was available. Routine data
226 quality checks were done regularly. To compare TB and HIV indicators across hospitals we
227 obtained data from the Lesotho District Health Information System 2 (DHIS 2)(41). Information
228 about social restrictions, COVID-19 policies modification, and COVID-19 national response in
229 Lesotho was compiled using the Lesotho Ministry of Health sources. Descriptive statistics
230 were used to characterize the study sample. Median and interquartile range (IQR) were
231 calculated to describe continuous variables, and frequencies and percentages for categorical
232 variables. Statistical analysis was performed using Stata (version 16.1, College Station, Tex:
233 StataCorp LP, 2007).

234 **Results**

235 Of the 179160 adults and children that were pre-screened, a total of 6623 (37%) had at least
236 one COVID-19 symptom or history of close contact with a COVID-19 or TB case. Amongst
237 those who pre-screened positive, a total of 4371 (66%) were enrolled in the integrated
238 TB/COVID-19/HIV testing procedures. The remaining 2252 (34%) participants that did not
239 enroll despite presenting symptoms were: 1) children below 5 years, 2) unaccompanied
240 children between the age of 7 and 17 years, 3) patients presenting in the weekends, when the
241 service was not available, 4) patients with severe symptoms that required immediate medical
242 attention, or 5) people who refuse to enroll in this service. Table 2 provides an overview of the
243 baseline characteristics of enrolled participants. A total of 2468 (61,7%) were adult women
244 and 369 (8.4%) were children and adolescents between the age of 5 and 17 years. Most of

245 them presented with at least one symptom, most commonly cough, or pronounced tiredness.
246 The median time from symptoms onset was 3 (IQR 2 -7) days, more than 98% presented with
247 mild or moderate symptoms and had an oxygen saturation $\geq 95\%$. A total of 1768 (44.1%)
248 adults had overweight or obesity (BMI ≥ 25 Kg/m²), 1058 (27.8%) had one elevated blood
249 pressure measurement ($\geq 140/90$ mmHg) , and 321 (8.0%) reported current tobacco use. A
250 total of 125 (3.7%) adults and 2 (0.6%) children reported a recent TB contact, while 111 (3.3%)
251 adults and 6 (1.9%) children reported a recent COVID-19 contact. A total of 814 adults (20.3%)
252 and 28 children (7.6%) reported to live with HIV.

253 **Integrated COVID-19/TB and HIV screening and testing model**

254 A summary of the diagnostic results is available in table 3. In terms of SARS-CoV-2 testing, a
255 total of 4355, 2421 and, 2664 nasopharyngeal RDT, nasal RDT, and nasopharyngeal PCR
256 tests were done. With regards to TB investigations, a total of 4371 chest x-rays were
257 performed, and overall, 884 (29.3%) participants had a CAD4TB score > 50 . For the 2419
258 participants who were eligible for sputum collection, 1454 samples were collected and tested
259 with Xpert MTB/RIF Ultra. Most common reasons for not collecting sputum included patient
260 refusing (377; 15,8%) or unable to produce a sample (263; 10.8%). A total of 104 people was
261 tested for HIV. Overall, a total of 458 new diagnoses were made, of which 383, 51 and 24
262 were COVID-19, TB, and HIV cases, respectively (table 3). Newly found cases were mainly
263 diagnosed among adults. Only 16 (4.3%) of the COVID-19 cases and 1 (1%) of the TB cases
264 were diagnosed in children and adolescent participants, and this model did not find any new
265 HIV diagnosis amongst them.

266 With regards to the clinical outcomes after four weeks of diagnosis, of the 458 people who
267 were diagnosed with either COVID-19, TB or HIV, a total of 321 (82.9%) participants, or their
268 relatives could be reached. Of those, 304 (94.7%) reported that they were healthy, whereas 5
269 (1.3%) reported to be ill or hospitalized (four people diagnosed with COVID-19 and one person
270 who was HIV positive). We recorded 12 (3.7%) participants who died in this period, however
271 we did not record the possible causes of death. Of the individuals that were newly diagnosed

272 with HIV or TB, a total of 18/24 (75.0%) and 46/51 (90.1%) had started ART and TB treatment
273 respectively, during this period (table 3).

274 The yield of this integrated testing model in terms of additional HIV, TB, and COVID-19
275 diagnosis across periods of different COVID-19 incidence is displayed in figure 3. Periods 1
276 and 4 (end of 2020 to mid-February 2021, and end of November 2021 to end of February
277 2022), are characterized by high SARS-COV-2 RDT positivity rates (20-40%), during very
278 short periods of time (distinct COVID-19 waves). Periods 3 and 5 (mid-June to end of
279 November 2021, and end of February to end of August 2022), are marked by lower SARS-
280 COV-2 RDT positivity rates across longer periods of time, indicating ongoing, low level of
281 community transmission. During period 2 (mid-February 2021 to Mid-June 2021), there were
282 almost no COVID-19 cases diagnosed at our sites. During periods of high COVID-19 incident
283 cases (1 and 4), when study staff had to cope with a larger number of enrolled participants,
284 the number of TB and HIV additional cases found was irregular. Whereas the periods of lower
285 COVID-19 incident cases allowed for a higher number of new TB and HIV diagnosis.

286 **Comparison performance of TB and HIV services with similar hospitals**

287 Figure 4 shows trends of HIV and TB new notifications, as well as the ART initiations, reported
288 in six hospitals Lesotho during the period of October 2020 to March 2022, using the Lesotho
289 DHIS-2 reporting system. Portrayed sites include the two study sites (Seboche Mission
290 Hospital and Mokhotlong Hospital), compared to Paray, St. James, Ntseke, and Tellebong
291 hospitals, where COVID-19 testing was conducted but not integrated with TB and HIV
292 services. All hospitals maintained HIV and TB services similarly during this period and the
293 Seboche and Mokhotlong hospitals, where this diagnostic model was implemented, seemed
294 to perform quite similarly.

295

296 **Discussion**

297 This observational study aimed to describe and assess the impact of an integrated COVID-
298 19, TB and HIV screening and testing service model in two hospitals in rural Lesotho, during
299 the period between December 2020 and August 2022. Our setting was characterized by an
300 overall low incidence of COVID-19 cases, a volatile context, and social restrictions in
301 continuous revision. Nonetheless, this service operated during two distinct COVID-19 waves
302 and two other periods when COVID-19 incident cases were continuously low. This pragmatic
303 diagnostic service model provided integrated diagnostic services to 4,371 adults and children,
304 who most frequently presented with non-severe symptoms, and previous contact with a TB or
305 COVID-19 case was unfrequently reported. The overall diagnostic yield, including COVID-19,
306 TB, and HIV, was 458 new cases, most frequently found in adults; only 17 (3.7%) of them
307 happened in children and adolescents.

308 It is almost certain that in this study we underestimate the number of COVID-19 and TB cases
309 diagnosed. In the case of COVID-19 cases, a PCR test was used as the gold standard for
310 diagnosis during most part of 2021. Later on, diagnosis was based on the result of the SARS-
311 CoV-2 STANDARD Q COVID-19 Ag test, that has shown relatively low diagnostic
312 performance in our setting (42). Anecdotically, a number of the 2252 (34%) eligible adults and
313 children that presented with symptoms but did not enroll in this service model despite being
314 eligible, were still tested for COVID-19 by the study staff, especially in periods where hospital
315 health staff in other departments was scarce, however, these individuals are not included in
316 this analysis. With regards to the definition of TB case in this study, we report only positive
317 Xpert MTB/RIF Ultra results in the sputum of participants, from whom we obtained a sample.
318 In our case, sputum samples could not be obtained for one third of the participants, mainly
319 due to refusals or inability to produce them. Additionally, for this analysis, we did not consider
320 a clinical TB diagnosis made by clinicians once a symptomatic patient was referred to further
321 evaluation by hospital staff.

322 To interpret these findings, it is also important to consider broader contextual factors that
323 played a role. One of them is related to the variation of circulating SARS-CoV-2 virus (Omicron

324 variant) and the lower diagnostic sensitivity observed using RDTs(43,44). In our setting, this
325 could have led to a lower detection or cases in symptomatic people seeking services. A
326 second factor could be related to the fluctuating access to hospital services. It is probable that
327 the changes imposed by the social restrictions, the availability of service providers
328 (themselves ill, in quarantine or isolated due to a recent contact), or the fear to acquire a
329 COVID-19 infection in the hospital, were important deterrents for symptomatic people to use
330 hospital services.

331 Of the 321 (82.9%) participants that were successfully reached after four weeks of the
332 diagnosis, 304 (94.7%), 18/24 (75%), and 46/53 (86.8%) were in good health, had started
333 ART and TB treatment respectively during this period. We recorded 12 (3.6%) participants
334 deaths, however, around one in six participants with a diagnosis could not be contacted in the
335 follow up period, therefore these results need to be interpreted with caution. Using the total
336 number of 4371 enrolled participants as a benchmark, we calculate that we found one SARS-
337 CoV-2 rapid antigen positive per 11 people screened, one Xpert MTB/RIF Ultra positive test
338 per 85 people screened, and 1 HIV new diagnosis was found per 182 people screened.

339 Surprisingly, we found no clear evidence to suggest that this resource-intense screening and
340 testing model had a significantly different impact in sustaining access to TB and HIV diagnostic
341 and treatment services, compared to similar hospitals in Lesotho, where this diagnostic model
342 was not in place, when referring to the Lesotho TB and HIV DHIS-2 reports. During the
343 analyzed period of October 2020 to March 2022, the number of HIV new diagnosis, ART
344 initiations, and TB case notifications in the six hospitals seem quite similar. Additionally, the
345 results from our study suggest that this diagnostic model had little impact on pediatric and
346 adolescent COVID-19, TB and HIV case finding in participants who were between the age of
347 5 and 18 years. On the other hand, the overall TB and HIV linkage to care rates within four
348 weeks of diagnosis were higher than reported in similar experiences(45–48), however when
349 comparing to global targets, this model fell short in ART initiation rates (75% vs 95%), and met
350 the TB treatment initiation target (90% vs. 90%)(49,50).

351 As the COVID-19 pandemic surged, and lockdowns led to the cancellation of essential health
352 services, global health actors advocated to adapt services that integrated TB, HIV and COVID-
353 19 activities in sub-Saharan Africa(29,42–44). This established an emerging body of evidence
354 that evaluates the experiences and successes in the integration of services. A study in
355 Uganda, using qualitative methods(34), reported that facilitators to integrate COVID-19 and
356 TB services included availability of focal health workers who were solely responsible for this
357 task, and availability of standard procedures and data collection tools. In this setting,
358 inconsistent supply of protective gear and fear of contracting COVID-19 decreased the
359 efficiency of the service. A study in Ethiopia reported a sharp reduction of TB service indicators
360 in Addis Ababa, partially mitigated with the use of digital health technology to screen for TB,
361 however, their results were not conclusive, due to lack of patient-level data(33). Another
362 similar experience in Niger and Guinea(54), found that out of the 863 individuals enrolled, 61
363 (7%) tested positive for COVID-19 and 43 (4.9%) were diagnosed with TB. These results are
364 comparable to our COVID-19 notifications in Lesotho (383, 8.8%), however, the investigators
365 in Niger and Guinea found a higher number of TB cases than in our setting [35 (4.6%) in
366 Guinea, 8 (7.6%) in Niger, and 51 (1.1%) in Lesotho]. Reports of pragmatic integrated
367 experiences aiming to sustain HIV testing and linkage to treatment amid the COVID-19
368 epidemic across sub-Saharan Africa are very scarce. A systematic review evaluating the
369 impact of the COVID-19 pandemic on accessing HIV services in South Africa, and an
370 evaluation of performance of services in primary health clinics(55,56) revealed that there were
371 significant decreases in HIV testing, positive HIV tests, and ART initiation at public health
372 facilities. However, the private facilities had maintained their activity similarly to pre-pandemic
373 levels, confirming a disparity in health access between the private and public sectors. In our
374 service, the routine use of the HIV testing screening tool targeted individuals who were most
375 at risk of a recent infection and yet, one in five people tested positive for HIV. However, it is
376 important to note that in our setting performing HIV testing depended greatly on the availability
377 of time that the study nurses had, while being burdened with other tasks. In periods of sharp
378 COVID-19-related overload, created by an increase of influx of individuals looking to be tested,

379 participants who were also eligible for HIV testing were referred to the routine hospital HIV
380 testing services. This was a result of an effort to maintain the function of the COVID-19
381 diagnostic services and the quality of the HIV testing service. This typically happened in a
382 different hospital department and could have decreased the efficiency to find new HIV cases.
383 Similarly to other published studies in sub-Saharan Africa and other regions of the world(33–
384 35,54,57–59), our integrated screening and diagnostic model proved to be a resource
385 intensive service, that had to adapt to contextual factors continuously. To ensure availability
386 and continuity of the service, we made significant investments in the deployment, protection,
387 training, and support of health staff.

388 Our study had various limitations. A major weakness is that we report on a hospital-based
389 screening and testing model, that served the population that voluntarily reached and enrolled
390 in the service. Therefore, our results refer to a selected population. By the end of 2021, SARS-
391 CoV-2 ag-RDTs became available at community level, through local retailers and primary
392 health clinics. As capacity for rapid testing for COVID-19 expanded, the population living in
393 these districts could choose where and how receive this service. Secondly, complementing
394 our study with qualitative approaches could have increased the efficiency, and acceptability of
395 the integrated diagnostic service, and explored the level and consequences of stigma related
396 to COVID-19 in our setting. However, these aspects were explored from the perspective of
397 the community in the two districts and will be reported in other studies. Lastly, an economic
398 analysis of this model could shed light on important questions related to health system-related
399 costs and patients-related costs. Despite these limitations, this is the first study evaluating the
400 effect of an integrated, COVID-19/TB and HIV diagnostic model in sub-Saharan Africa,
401 covering a period of 22 months and reporting on disaggregated characteristics and outcomes
402 in adults and children above 5 years.

403

404 **Conclusion**

405 This study shows that integrated testing for TB/COVID-19 and HIV is feasible in resource-
406 constraint, routine programmatic settings. Our findings provide information to support health
407 system managers and policy makers in the design of services that integrate COVID-19
408 aspects. Continuous surveillance of COVID-19 incident cases, availability of health staff, and
409 routine monitoring of diagnostic yields are important aspects to adapt these services and find
410 efficiencies in such rapid-evolving contexts.

411

412

413 **Declarations**

414

415 **Ethics approval and consent to participate**

416 This project was approved by the Lesotho Ministry of Health Ethics Committee (ID 107-2020)
417 and by the Ethic Committee Switzerland (EthikkommissioNordwest-und Zentralschweiz
418 (EKNZ) AO_2020-00018)

419 **Consent for publication**

420 All authors consent to the publication of this manuscript.

421

422 **Availability of data and materials**

423 All data generated or analyzed during this study are included in this published article [and its
424 supplementary information files]. All articles used for the review are in the references section.

425

426 **Competing interests**

427 None declared

428

429 **Funding**

430 Funding was provided by the Botnar Research Centre for Child Health (to Dr. Klaus Reither)
431 in June 2020.

432

433 **Author Contributions**

434 BK, KR, and LGF conceptualized the study and design. BK, MB, RME, TG performed
435 references screening, data collection and summarization. BK, KR, and LGF drafted the
436 manuscript. All authors reviewed the results and approved the final version of the manuscript.

437

438

439

440

441

442

443 **References**

- 444 1. Kendzerska T, Zhu DT, Gershon AS, Edwards JD, Peixoto C, Robillard R, et al. The Effects of the
445 Health System Response to the COVID-19 Pandemic on Chronic Disease Management: A
446 Narrative Review. *Risk Manag Healthc Policy*. 2021;14:575–84.
- 447 2. Moynihan R, Sanders S, Michaleff ZA, Scott AM, Clark J, To EJ, et al. Impact of COVID-19
448 pandemic on utilisation of healthcare services: a systematic review. *BMJ Open*. 2021 Mar
449 16;11(3):e045343.
- 450 3. Arsenault C, Gage A, Kim MK, Kapoor NR, Akweongo P, Amponsah F, et al. COVID-19 and
451 resilience of healthcare systems in ten countries. *Nat Med*. 2022 Jun;28(6):1314–24.
- 452 4. Third round of the global pulse survey on continuity of essential health services during the
453 COVID-19 pandemic: November - December 2021: interim report, 7 February 2022 - World |
454 ReliefWeb [Internet]. [cited 2022 Dec 2]. Available from:
455 [https://reliefweb.int/report/world/third-round-global-pulse-survey-continuity-essential-health-](https://reliefweb.int/report/world/third-round-global-pulse-survey-continuity-essential-health-services-during-covid-19)
456 [services-during-covid-19](https://reliefweb.int/report/world/third-round-global-pulse-survey-continuity-essential-health-services-during-covid-19)
- 457 5. World Health Organization. Maintaining essential health services: operational guidance for the
458 COVID-19 context. World Health Organization. 2020;(June):55.
- 459 6. PATH. Essential health services during and after COVID-19: A sprint analysis of disruptions and
460 responses across six countries. 2020;(December):26.
- 461 7. Global Tuberculosis Report 2022 [Internet]. [cited 2022 Dec 1]. Available from:
462 [https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022)
463 [report-2022](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022)
- 464 8. HIV and COVID-19 [Internet]. [cited 2022 Dec 1]. Available from:
465 <https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/covid-19>
- 466 9. Nachega J, Seydi M, Zumla A. The late arrival of coronavirus disease 2019 (COVID-19) in Africa:
467 Mitigating pan-continental spread. *Clinical Infectious Diseases*. 2020;71(15):875–8.
- 468 10. Holtzman CW, Godfrey C, Ismail L, Raizes E, Ake JA, Tefera F, et al. PEPFAR’s Role in Protecting
469 and Leveraging HIV Services in the COVID-19 Response in Africa. *Current HIV/AIDS Reports*.
470 2022;19(1):26–36.
- 471 11. Tessema GA, Kinfu Y, Dachew BA, Tesema AG, Assefa Y, Alene KA, et al. The COVID-19 pandemic
472 and healthcare systems in Africa: A scoping review of preparedness, impact and response. *BMJ*
473 *Global Health*. 2021;6(12):1–14.
- 474 12. Dorward J, Khubone T, Gate K, Ngobese H, Sookrajh Y, Mkhize S, et al. The impact of the COVID-
475 19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series
476 analysis. *The Lancet HIV* [Internet]. 2021 Mar 1 [cited 2022 Dec 1];8(3):e158–65. Available from:
477 [https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018\(20\)30359-3/fulltext](https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30359-3/fulltext)
- 478 13. Population, total - Lesotho | Data [Internet]. [cited 2022 Dec 14]. Available from:
479 <https://data.worldbank.org/indicator/SP.POP.TOTL?locations=LS>

- 480 14. TB profile [Internet]. [cited 2022 Nov 25]. Available from:
481 [https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=](https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22LS%22)
482 [%22EN%22&iso2=%22LS%22](https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22LS%22)
- 483 15. Schwitters A, McCracken S, Frederix K, Tierney R, Koto M, Ahmed N, et al. High HIV prevalence
484 and associated factors in Lesotho: Results from a population-based survey. PLOS ONE [Internet].
485 2022 Jul 28 [cited 2022 Nov 25];17(7):e0271431. Available from:
486 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271431>
- 487 16. Lesotho [Internet]. [cited 2022 Dec 11]. Available from:
488 <https://www.unaids.org/en/regionscountries/countries/lesotho>
- 489 17. COVID-19 Preparedness in Lesotho [Internet]. THET. [cited 2022 Nov 26]. Available from:
490 <https://www.thet.org/case-studies/covid-19-preparedness-in-lesotho/>
- 491 18. Family planning uptake drops in Lesotho due to COVID-19 restrictions, analysis shows - Lesotho
492 | ReliefWeb [Internet]. [cited 2022 Nov 26]. Available from:
493 [https://reliefweb.int/report/lesotho/family-planning-uptake-drops-lesotho-due-covid-19-](https://reliefweb.int/report/lesotho/family-planning-uptake-drops-lesotho-due-covid-19-restrictions-analysis-shows)
494 [restrictions-analysis-shows](https://reliefweb.int/report/lesotho/family-planning-uptake-drops-lesotho-due-covid-19-restrictions-analysis-shows)
- 495 19. Sanders JE, Chakare T, Mapota-Masoabi L, Ranyali-Otubanjo M, Ramokhele MM, Rozario A, et
496 al. National hospital readiness for COVID-19 in Lesotho: Evidence for oxygen ecosystem
497 strengthening [Internet]. medRxiv; 2021 [cited 2022 Nov 26]. p. 2021.04.27.21256199. Available
498 from: <https://www.medrxiv.org/content/10.1101/2021.04.27.21256199v1>
- 499 20. Nyangu I, Ramathebane M. Perceptions of Healthcare Professionals on COVID-19 in Lesotho: A
500 Cross-Sectional Survey. Journal of Biosciences and Medicines [Internet]. 2022 Jan 29 [cited 2022
501 Nov 26];10(2):39–50. Available from:
502 <http://www.scirp.org/Journal/Paperabs.aspx?paperid=115129>
- 503 21. Lesotho-Humanitarian-SitRep-June-2021.pdf [Internet]. [cited 2022 Dec 11]. Available from:
504 <https://www.unicef.org/media/104171/file/Lesotho-Humanitarian-SitRep-June-2021.pdf>
- 505 22. Lesotho: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data [Internet].
506 [cited 2022 Nov 26]. Available from: <https://covid19.who.int>
- 507 23. Release AP. Lesotho Moves to Green Code Colour Stage [Internet]. [cited 2022 Nov 26].
508 Available from: [https://www.zawya.com/en/press-release/africa-press-releases/lesotho-moves-](https://www.zawya.com/en/press-release/africa-press-releases/lesotho-moves-to-green-code-colour-stage-g26m14mn)
509 [to-green-code-colour-stage-g26m14mn](https://www.zawya.com/en/press-release/africa-press-releases/lesotho-moves-to-green-code-colour-stage-g26m14mn)
- 510 24. LESOTHO MOVES TO BLUE COLOUR CODING STAGE – Government Of Lesotho [Internet]. [cited
511 2022 Nov 26]. Available from: <https://www.gov.ls/lesotho-moves-to-blue-colour/>
- 512 25. Lesotho_2020.08.24_Regulation_Public-Health-COVID-19-Risk-Determination-and-Mitigation-
513 Measures-No.-3-Regulations-2020_EN_.pdf [Internet]. [cited 2022 Nov 26]. Available from:
514 [https://covidlawlab.org/wp-content/uploads/2022/01/Lesotho_2020.08.24_Regulation_Public-](https://covidlawlab.org/wp-content/uploads/2022/01/Lesotho_2020.08.24_Regulation_Public-Health-COVID-19-Risk-Determination-and-Mitigation-Measures-No.-3-Regulations-2020_EN_.pdf)
515 [Health-COVID-19-Risk-Determination-and-Mitigation-Measures-No.-3-Regulations-](https://covidlawlab.org/wp-content/uploads/2022/01/Lesotho_2020.08.24_Regulation_Public-Health-COVID-19-Risk-Determination-and-Mitigation-Measures-No.-3-Regulations-2020_EN_.pdf)
516 [2020_EN_.pdf](https://covidlawlab.org/wp-content/uploads/2022/01/Lesotho_2020.08.24_Regulation_Public-Health-COVID-19-Risk-Determination-and-Mitigation-Measures-No.-3-Regulations-2020_EN_.pdf)
- 517 26. Public-Health-Covid-19-risk-Determination-and-Mitigation-Measure-No.5-Amendment-
518 Regulations-2022.pdf [Internet]. [cited 2022 Nov 26]. Available from:
519 [https://kleingeldmayet.co.ls/wp-content/uploads/2022/01/Public-Health-Covid-19-risk-](https://kleingeldmayet.co.ls/wp-content/uploads/2022/01/Public-Health-Covid-19-risk-Determination-and-Mitigation-Measure-No.5-Amendment-Regulations-2022.pdf)
520 [Determination-and-Mitigation-Measure-No.5-Amendment-Regulations-2022.pdf](https://kleingeldmayet.co.ls/wp-content/uploads/2022/01/Public-Health-Covid-19-risk-Determination-and-Mitigation-Measure-No.5-Amendment-Regulations-2022.pdf)

- 521 27. kleingeld. Lesotho Covid-19 Resource Portal – Adjusted Blue Colour Code [Internet]. Kleingeld &
522 Mayet. 2022 [cited 2022 Nov 26]. Available from: [https://kleingeldmayet.co.ls/lesotho-covid-19-](https://kleingeldmayet.co.ls/lesotho-covid-19-resource-portal-adjusted-blue-colour-code/)
523 [resource-portal-adjusted-blue-colour-code/](https://kleingeldmayet.co.ls/lesotho-covid-19-resource-portal-adjusted-blue-colour-code/)
- 524 28. NNN. Lesotho moves to green code color stage [Internet]. NNN. 2022 [cited 2022 Nov 26].
525 Available from: <https://nnn.ng/lesotho-moves-to-green-code-color-stage/>
- 526 29. Mistral: Mitigation Strategies for Communities With COVID-19 Transmission in Lesotho Using
527 Artificial Intelligence on Chest X-rays and Novel Rapid Diagnostic Tests – BRCC [Internet]. [cited
528 2022 Nov 26]. Available from: <https://brc.ch/research/mistral/>
- 529 30. Ruhwald M, Hannay E, Sarin S, Kao K, Sen R, Chadha S. Considerations for simultaneous testing
530 of COVID-19 and tuberculosis in high-burden countries. *The Lancet Global Health* [Internet].
531 2022 Apr 1 [cited 2022 Nov 25];10(4):e465–6. Available from:
532 [https://www.thelancet.com/journals/langlo/article/PIIS2214-109X\(22\)00002-X/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(22)00002-X/fulltext)
- 533 31. MacLean EL, Villa-Castillo L, Ruhwald M, Ugarte-Gil C, Pai M. Integrated testing for TB and
534 COVID-19. *Med (N Y)* [Internet]. 2022 Mar 11 [cited 2022 Nov 25];3(3):162–6. Available from:
535 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831149/>
- 536 32. Holtzman CW, Godfrey C, Ismail L, Raizes E, Ake JA, Tefera F, et al. PEPFAR’s Role in Protecting
537 and Leveraging HIV Services in the COVID-19 Response in Africa. *Curr HIV/AIDS Rep* [Internet].
538 2022 [cited 2022 Nov 25];19(1):26–36. Available from:
539 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724594/>
- 540 33. Arega B, Negesso A, Taye B, Weldeyohhans G, Bewket B, Negussie T, et al. Impact of COVID-19
541 pandemic on TB prevention and care in Addis Ababa, Ethiopia: a retrospective database study.
542 *BMJ Open* [Internet]. 2022 Feb 8 [cited 2022 Nov 25];12(2):e053290. Available from:
543 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829833/>
- 544 34. Semitala FC, Katwesigye R, Kalibbala D, Mbuliro M, Opio R, Owachi D, et al. Integration of
545 COVID-19 and TB screening in Kampala, Uganda - Healthcare provider perspectives. *Res Sq*
546 [Internet]. 2022 Jun 7 [cited 2022 Nov 25];rs.3.rs-1448831. Available from:
547 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196119/>
- 548 35. Njau A, Kimeu J, Gohil J, Nganga D. Informing healthcare operations with integrated pathology,
549 clinical, and epidemiology data: Lessons from a single institution in Kenya during COVID-19
550 waves. *Front Med (Lausanne)*. 2022;9:969640.
- 551 36. Reichler MR, Khan A, Yuan Y, Chen B, McAuley J, Mangura B, et al. Duration of Exposure Among
552 Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection.
553 *Clinical Infectious Diseases* [Internet]. 2020 Oct 23 [cited 2022 Dec 15];71(7):1627–34. Available
554 from: <https://doi.org/10.1093/cid/ciz1044>
- 555 37. Qin ZZ, Ahmed S, Sarker MS, Paul K, Adel ASS, Naheyan T, et al. Tuberculosis detection from
556 chest x-rays for triaging in a high tuberculosis-burden setting: an evaluation of five artificial
557 intelligence algorithms. *The Lancet Digital Health* [Internet]. 2021 Sep 1 [cited 2022 Dec
558 11];3(9):e543–54. Available from: [https://www.thelancet.com/journals/landig/article/PIIS2589-](https://www.thelancet.com/journals/landig/article/PIIS2589-7500(21)00116-3/fulltext)
559 [7500\(21\)00116-3/fulltext](https://www.thelancet.com/journals/landig/article/PIIS2589-7500(21)00116-3/fulltext)
- 560 38. Linkages across the Continuum of HIV Services for Key Populations Affected by HIV (LINKAGES):
561 Country Resources [Internet]. FHI 360. [cited 2022 Dec 2]. Available from:

- 562 [https://www.fhi360.org/resource/linkages-across-continuum-hiv-services-key-populations-](https://www.fhi360.org/resource/linkages-across-continuum-hiv-services-key-populations-affected-hiv-linkages-country)
563 [affected-hiv-linkages-country](https://www.fhi360.org/resource/linkages-across-continuum-hiv-services-key-populations-affected-hiv-linkages-country)
- 564 39. WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for
565 Medical Research Involving Human Subjects [Internet]. [cited 2022 Nov 25]. Available from:
566 [https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/)
567 [research-involving-human-subjects/](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/)
- 568 40. Open Data Kit [Internet]. Open Data Kit. 2018 [cited 2022 Dec 1]. Available from:
569 <https://opendatakit.org/>
- 570 41. Improving DHIS2 Integration for Lesotho’s Health Information Ecosystem - Implementation -
571 Implémentation / Interoperability [Internet]. DHIS2 Community. 2022 [cited 2022 Nov 25].
572 Available from: [https://community.dhis2.org/t/improving-dhis2-integration-for-lesothos-health-](https://community.dhis2.org/t/improving-dhis2-integration-for-lesothos-health-information-ecosystem/47463)
573 [information-ecosystem/47463](https://community.dhis2.org/t/improving-dhis2-integration-for-lesothos-health-information-ecosystem/47463)
- 574 42. Labhardt ND, Fernández LG, Katende B, Muhairwe J, Bresser M, Amstutz A, et al. Head-to-head
575 comparison of nasal and nasopharyngeal sampling using SARS-CoV-2 rapid antigen testing in
576 Lesotho [Internet]. medRxiv; 2022 [cited 2022 Dec 2]. p. 2021.12.29.21268505. Available from:
577 <https://www.medrxiv.org/content/10.1101/2021.12.29.21268505v1>
- 578 43. Use of Rapid Antigen Tests during the Omicron Wave [Internet]. Ontario COVID-19 Science
579 Advisory Table. [cited 2022 Dec 13]. Available from: [https://covid19-](https://covid19-science.ca/sciencebrief/use-of-rapid-antigen-tests-during-the-omicron-wave/)
580 [science.ca/sciencebrief/use-of-rapid-antigen-tests-during-the-omicron-wave/](https://covid19-science.ca/sciencebrief/use-of-rapid-antigen-tests-during-the-omicron-wave/)
- 581 44. Bekliz M, Adea K, Puhach O, Perez-Rodriguez F, Marques Melancia S, Baggio S, et al. Analytical
582 Sensitivity of Eight Different SARS-CoV-2 Antigen-Detecting Rapid Tests for Omicron-BA.1
583 Variant. *Microbiology Spectrum* [Internet]. 2022 Aug 8 [cited 2022 Dec 13];10(4):e00853-22.
584 Available from: <https://journals.asm.org/doi/10.1128/spectrum.00853-22>
- 585 45. Chawla KS, Kanyama C, Mbewe A, Matoga M, Hoffman I, Ngoma J, et al. Policy to practice:
586 impact of GeneXpert MTB/RIF implementation on the TB spectrum of care in Lilongwe, Malawi.
587 *Transactions of The Royal Society of Tropical Medicine and Hygiene* [Internet]. 2016 May 1
588 [cited 2022 Dec 2];110(5):305–11. Available from: <https://doi.org/10.1093/trstmh/trw030>
- 589 46. Shapiro AE, van Heerden A, Schaafsma TT, Hughes JP, Baeten JM, van Rooyen H, et al.
590 Completion of the tuberculosis care cascade in a community-based HIV linkage-to-care study in
591 South Africa and Uganda. *J Int AIDS Soc* [Internet]. 2018 Jan 30 [cited 2022 Dec 2];21(1):e25065.
592 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810338/>
- 593 47. Katende B, Esterhuizen TM, Dippenaar A, Warren RM. Rifampicin Resistant Tuberculosis in
594 Lesotho: Diagnosis, Treatment Initiation and Outcomes. *Sci Rep* [Internet]. 2020 Feb 5 [cited
595 2022 Dec 2];10(1):1–8. Available from: <https://www.nature.com/articles/s41598-020-58690-4>
- 596 48. Mabote N, Mamo M, Nsakala B, Lanje S, Mwanawabene NR, Katende B. Linkage to care and
597 treatment outcomes for patients diagnosed with drug-susceptible tuberculosis using Xpert
598 MTB/RIF assay in Thaba-Tseka district in Lesotho. *IJID Regions* [Internet]. 2022 Dec 1 [cited 2022
599 Dec 2];5:33–8. Available from:
600 <https://www.sciencedirect.com/science/article/pii/S2772707622001047>
- 601 49. LESOTHO TB Dashboard [Internet]. [cited 2022 Nov 26]. Available from:
602 https://www.stoptb.org/static_pages/LSO_Dashboard.html

- 603 50. Lesotho [Internet]. [cited 2022 Nov 26]. Available from:
604 <https://www.unaids.org/en/regionscountries/countries/lesotho>
- 605 51. PCB48_Thematic_Segment_Background_Note_EN.rev2_.pdf [Internet]. [cited 2022 Nov 25].
606 Available from:
607 https://www.unaids.org/sites/default/files/media_asset/PCB48_Thematic_Segment_Background_Note_EN.rev2_.pdf
608
- 609 52. WHO supports government to integrate COVID-19 case finding into TB surveillance activities.
610 [Internet]. WHO | Regional Office for Africa. [cited 2022 Nov 25]. Available from:
611 <https://www.afro.who.int/news/who-supports-government-integrate-covid-19-case-finding-tb-surveillance-activities>
612
- 613 53. Strategic considerations for mitigating the impact of COVID-19 on key-population-focused HIV
614 programs [Internet]. [cited 2022 Dec 2]. Available from:
615 <https://www.unaids.org/en/resources/documents/2020/key-populations-strategic-considerations-covid19>
616
- 617 54. Magassouba AS, Bassirou SM, Touré AA, Diallo BD, Alphazazi S, Cissé D, et al. Evaluating the
618 Effectiveness of a Novel Systematic Screening Approach for Tuberculosis among Individuals
619 Suspected or Recovered from COVID-19: Experiences from Niger and Guinea. *Tropical Medicine
620 and Infectious Disease* [Internet]. 2022 Sep [cited 2022 Dec 13];7(9):228. Available from:
621 <https://www.mdpi.com/2414-6366/7/9/228>
- 622 55. Dorward J, Khubone T, Gate K, Ngobese H, Sookrajh Y, Mkhize S, et al. The impact of the COVID-
623 19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series
624 analysis. *Lancet HIV*. 2021 Mar;8(3):e158–65.
- 625 56. Jardim CGR, Zamani R, Akrami M. Evaluating the Impact of the COVID-19 Pandemic on Accessing
626 HIV Services in South Africa: A Systematic Review. *Int J Environ Res Public Health* [Internet].
627 2022 Sep 21 [cited 2022 Nov 25];19(19):11899. Available from:
628 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565529/>
- 629 57. Khobragade RN, Murthy N, Aloysius S, Surendran D, Rakesh PS, Balakrishnan S. Experience of
630 integrated screening and testing for TB and COVID19 from Kerala, India. *Public Health Pract
631 (Oxf)* [Internet]. 2021 Oct 2 [cited 2022 Nov 25];2:100198. Available from:
632 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486580/>
- 633 58. Malik AA, Hussain H, Maniar R, Safdar N, Mohiuddin A, Riaz N, et al. Integrated Tuberculosis and
634 COVID-19 Activities in Karachi and Tuberculosis Case Notifications. *Trop Med Infect Dis*
635 [Internet]. 2022 Jan 15 [cited 2022 Nov 25];7(1):12. Available from:
636 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778721/>
- 637 59. Muñoz-Salazar R, Le T, Cuevas-Mota J, González-Fagoaga JE, Zapata-Garibay R, Ruiz-Tamayo PS,
638 et al. Impact of COVID-19 on tuberculosis detection and treatment in Baja California, México.
639 *Front Public Health* [Internet]. 2022 Jul 22 [cited 2022 Nov 25];10:921596. Available from:
640 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356343/>

641

642

643

644

645

646